Cardiovascular Complications in Patients With COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 198
- 试验地点
- 8
- 主要终点
- Determine the incidence of cardiomyopathies and venous thromboembolism
研究概览
简要总结
Patients with COVID-19 in the Intensive Care Unit (ICU) or hospitalized with severe form have a poor prognosis (almost 30% rate of death). They present often a high cardiovascular risk profile (almost 30% of hypertension and 19% of diabetes). Troponin has been described to be elevated in a high proportion of patients (one fifth of all patients and 50% of non-survivors) suggesting the possibility of cardiomyopathies. High levels of DDimers (81% of non survivors) and fibrin degradation products are also associated with increased risk of mortality suggesting also the possibility of venous thromboembolism. Therefore, screening for cardiomyopathies and venous thromboembolism could represent an important challenge for patients with COVID-19 management.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •All consecutive patients with COVID-19 infection admitted to the ICU or hospitalized because of severe form (eg: hypoxia, orthopnea, pneumonitis, kidney insufficiency) will be included
排除标准
- •Patients under 18 years
结局指标
主要结局
Determine the incidence of cardiomyopathies and venous thromboembolism
时间窗: 28 days
Incidence of cardiomyopathies and/or venous thromboembolism at day 28
次要结局
- Mortality(28 days)
- Duration of mechanical ventilation(hospitalisation duration)
- Shock(hospitalisation duration)
- Renal replacement therapy(hospitalisation duration)
- length of stay(hospitalisation duration)
- Mechanical ventilation(hospitalisation duration)